The Disks Large Homolog 4 pipeline drugs market research report outlays comprehensive information on the Disks Large Homolog 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Disks Large Homolog 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, and Ophthalmology which include the indications Acute Ischemic Stroke, Subarachnoid Hemorrhage, Unspecified Central Nervous System Disorders, Traumatic Brain Injury, and Ophthalmology. It also reviews key players involved in Disks Large Homolog 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Disks Large Homolog 4 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 3, 1, and 2 respectively.
Disks Large Homolog 4 overview
Disks Large Homolog 4 is a protein encoded by a gene DLG4. DLG4 is a member of the membrane-associated guanylate kinase (MAGUK) family. This protein plays a critical role in synaptogenesis and synaptic plasticity by providing a platform for the postsynaptic clustering of crucial synaptic proteins. It heteromultimerizes with another MAGUK protein, DLG2, and is recruited into NMDA receptor and potassium channel clusters. These two MAGUK proteins may interact at postsynaptic sites to form a multimeric scaffold for the clustering of receptors, ion channels, and associated signaling proteins.
For a complete picture of Disks Large Homolog 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
